Ramucirumab and Carbo-Paclitaxel for Untreated Thymic Carcinoma / B3 Thymoma With Carcinoma (RELEVENT)
Clinical trial NCT03921671 · UNKNOWN
Trial details
- NCT number
- NCT03921671
- Sponsor
- Claudia Proto
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-11-01
- Primary completion
- 2021-10-09
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.